Design of advanced siRNA therapeutics for the treatment of COVID-19

被引：16

作者：

Niktab, Iman ^{[1
,2
]}

Haghparast, Maryam ^{[1
]}

Beigi, Mohammad-Hossein ^{[1
,3
]}

Megraw, Timothy L. ^{[4
]}

Kiani, Amirkianoosh ^{[3
]}

Ghaedi, Kamran ^{[1
]}

机构：

[1] Univ Isfahan, Fac Biol Sci & Technol, Dept Cell & Mol Biol & Microbiol, Hezar Jerib Ave,Azadi Sq, Esfahan 8174673441, Iran

[2] Shahid Bahonar Univ Kerman, Dept Biol, Fac Sci, Kerman, Iran

[3] Ontario Tech Univ, Fac Engn & Appl Sci, Silicon Hall Micro Nano Mfg Facil, Oshawa, ON, Canada

[4] Florida State Univ, Coll Med, Dept Biomed Sci, West Call St, Tallahassee, FL 32306 USA

来源：

META GENE | 2021年 / 29卷

基金：

加拿大自然科学与工程研究理事会;

关键词：

siRNAs; COVID-19; SARS-CoV-2; qRT-PCR; SARS-COV; DISEASE; KNOCKING; PROGRESS;

D O I：

10.1016/j.mgene.2021.100910

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

COVID-19 is a newly emerged viral disease that is currently affecting the whole globe. A variety of therapeutic approaches are underway to block the SARS-CoV-2 virus. Among these methods, siRNAs could be a safe and specific option, as they have been tested against other viruses. siRNAs are a class of inhibitor RNAs that act promisingly as mRNA expression blockers and they can be designed to interfere with viral mRNA to block virus replication. In order to do this, we designed and evaluated the efficacy of six highly specific siRNAs, which target essential viral mRNAs with no predicted human genome off-targets. We observed a significant reduction in the copy number viral mRNAs after treatment with the siRNAs, and are expected to inhibit virus replication. We propose siRNAs as a potential co-therapy for acute SARS-CoV-2 infection.

引用

页数：4

共 50 条

[41] An update on emerging therapeutics to combat COVID-19
Shah, Naveed Nazir
Nabi, Showkat Ul
Rather, Muzafar Ahmad
Kalwar, Qudratullah
Ali, Sofi Imtiyaz
Sheikh, Wajid Mohammad
Ganai, Alveena
Bashir, Showkeen Muzamil
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 129 (02) : 104 - 129
[42] Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
Chen, Xingchen
Luo, Yujia
[J]. JOURNAL OF PAIN RESEARCH, 2023, 16 : 111 - 117
[43] Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery
Fopase, Rushikesh
Panda, Chinmaya
Rajendran, Amarnath P.
Uludag, Hasan
Pandey, Lalit M.
[J]. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
[44] Clinical status of potential drugs used for COVID-19 treatment and recent advances in new therapeutics - A review
Mandal, Kalpa
Singh, Meenakshi
Chandra, Charu
Kumawat, Indraj
[J]. CHEMICAL BIOLOGY LETTERS, 2021, 8 (03): : 117 - 128
[45] COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Dhanusha Yesudhas
Ambuj Srivastava
M. Michael Gromiha
[J]. Infection, 2021, 49 : 199 - 213
[46] COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics
Spihlman, Allison P.
Gadi, Nirupa
Wu, Samantha C.
Moulton, Vaishali R.
[J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
[47] COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Yesudhas, Dhanusha
Srivastava, Ambuj
Gromiha, M. Michael
[J]. INFECTION, 2021, 49 (02) : 199 - 213
[48] COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
Tripathi, Neetu
Tripathi, Neeraj
Goshisht, Manoj Kumar
[J]. MOLECULAR DIVERSITY, 2022, 26 (01) : 629 - 645
[49] COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
Neetu Tripathi
Neeraj Tripathi
Manoj Kumar Goshisht
[J]. Molecular Diversity, 2022, 26 : 629 - 645
[50] Emerging Technologies for the Treatment of COVID-19
Aghamollaei, Hossein
Sarvestani, Rahim
Bakherad, Hamid
Zare, Hamed
Guest, Paul C.
Ranjbar, Reza
Sahebkar, Amirhossein
[J]. CLINICAL, BIOLOGICAL AND MOLECULAR ASPECTS OF COVID-19, 2021, 1321 : 81 - 96

← 1 2 3 4 5 →